18F‐flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study
Open accessAbstract
Objective: 18 F‐flortaucipir (formerly 18 F‐AV1451 or 18 F‐T807) binds to neurofibrillary tangles in Alzheimer disease, but tissue studies assessing binding to tau aggregates in progressive supranuclear palsy (PSP) have yielded mixed results. We compared in vivo 18 F‐flortaucipir uptake in patients meeting clinical research criteria for PSP (n = 33) to normal controls (n = 46) and patients meeting criteria for Parkinson disease (PD; n = 26). Methods: Participants underwent magnetic resonance imaging and positron emission tomography for amyloid‐β (11 C‐PiB or 18 F‐florbetapir) and tau (18 F‐flortaucipir). 18 F‐flortaucipir standardized uptake value ratios were calculated (t = 80–100 minutes, cerebellum gray matter reference). Voxelwise and region‐of‐interest group comparisons were performed in template space, with receiver operating characteristic curve analyses to assess single‐subject discrimination. Qualitative comparisons with postmortem tau are reported in 1 patient who died 9 months after 18 F‐flortaucipir. Results: Clinical PSP patients showed bilaterally elevated 18 F‐flortaucipir uptake in globus pallidus, putamen, subthalamic nucleus, midbrain, and dentate nucleus relative to controls and PD patients (voxelwise p < 0.05 family wise error corrected). Globus pallidus binding best distinguished PSP patients from controls and PD (area under the curve [AUC] = 0.872 vs controls, AUC = 0.893 vs PD). PSP clinical severity did not correlate with 18 F‐flortaucipir in any region. A patient with clinical PSP and pathological diagnosis of corticobasal degeneration had severe tau pathology in PSP‐related brain structures with good correspondence between in vivo 18 F‐flortaucipir and postmortem tau neuropathology. Interpretation: 18 F‐flortaucipir uptake was elevated in PSP versus controls and PD patients in a pattern consistent with the expected distribution of tau pathology. Ann Neurol 2017;82:622–634
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Earlier PET investigations have detected alterations in PSP with ligands for tau and for microglial activation.
“Previous positron emission tomography (PET) has indicated changes in PSP using ligands targeting tau8–16 and microglial activation17,18.”
From Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy (2020) · cites this paper as [16]
Only a few previous studies have explored how [11C]PK11195 and [18F]AV-1451 binding relate to disease severity in PSP.
“This finding adds relevant information to the literature as only a few previous studies have explored how [11C]PK11195 and [18F]AV-1451 binding relate to disease severity in PSP8,9,13,14,16,18.”
From Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy (2020) · cites this paper as [16]
In PSP, higher [18F]AV-1451 binding is found in subcortical rather than cortical regions, consistent with the known distribution of PSP-Richardson's syndrome.
“In PSP, higher [18F]AV-1451 binding has been found in sub-cortical rather than cortical regions (the reverse for AD), consistent with the well-established cortical versus sub-cortical distribution of PSP-Richardson’s syndrome8–10,13,14,16.”
From Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy (2020) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481 · see citing works
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · see citing works
Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders · doi:10.1002/mds.24893 · Cited by 2,609 · see citing works
Self-citationLitvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538 · see citing works
Self-citationClinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,374 · see citing works
Self-citationCriteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904 · see citing works
Self-citationA probabilistic MR atlas of the human cerebellum
Diedrichsen, J., Balsters, J. H., Flavell, J. C., Cussans, E., & Ramnani, N. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.01.045 · Cited by 1,370 · see citing works
PET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214 · see citing works
Self-citationTau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185 · see citing works
Self-citationUse of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117 · see citing works
A harmonized classification system for FTLD-TDP pathology
Mackenzie, I. R., Neumann, M., Baborie, A., Sampathu, D. M., du Plessis, D., Jaros, E., Perry, R. H., Trojanowski, J. Q., Mann, D. M. A., & Lee, V. M. ‐. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0845-8 · Cited by 1,013 · see citing works
Tau positron emission tomographic imaging in aging and early <scp>A</scp> lzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986 · see citing works
Self-citationCorrection for partial volume effects in PET: principle and validation.
ROUSSET, O. G., Ma, Y., & Evans, A. C. (1998) · PubMed · Cited by 919 · see citing works
Hauw, J., Daniel, S. E., Dickson, D. W., Horoupian, D. S., Jellinger, K. A., Lantos, P. L., McKee, A. C., Tabaton, M., & Litvan, I. (1994) · Neurology · doi:10.1212/wnl.44.11.2015 · Cited by 854 · see citing works
Self-citationMaruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760 · see citing works
Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration
Dickson, D. W., Bergeron, C., Chin, S. S., Duyckaerts, C., Horoupian, D., Ikeda, K., Jellinger, K., Lantos, P. L., Lippa, C. F., Mirra, S. S., et al. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.11.935 · Cited by 724 · see citing works
Self-citationProgressive supranuclear palsy: clinicopathological concepts and diagnostic challenges
Williams, D. R., & Lees, A. J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70042-0 · Cited by 650 · see citing works
Marquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615 · see citing works
Self-citationA clinical rating scale for progressive supranuclear palsy
Golbe, L. I., & Ohman‐Strickland, P. (2007) · Brain · doi:10.1093/brain/awm032 · Cited by 614 · see citing works
An autoradiographic evaluation of AV-1451 Tau PET in dementia
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0315-6 · Cited by 474 · see citing works
Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration
Dickson, D. W. (1999) · Journal of Neurology · doi:10.1007/bf03161076 · Cited by 424 · see citing works
Williams, D. R., Holton, J. L., Strand, C., Pittman, A. M., de Silva, R., Lees, A. J., & Révész, T. (2007) · Brain · doi:10.1093/brain/awm104 · Cited by 415 · see citing works
Villeneuve, S., Rabinovici, G. D., Cohn-Sheehy, B. I., Madison, C., Ayakta, N., Ghosh, P. M., La Joie, R., Arthur-Bentil, S. K., Vogel, J. W., Marks, S. M., et al. (2015) · Brain · doi:10.1093/brain/awv112 · Cited by 408 · see citing works
Self-citationNeuropathology of variants of progressive supranuclear palsy
Dickson, D. W., Ahmed, Z., Algom, A. A., Tsuboi, Y., & Josephs, K. A. (2010) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32833be924 · Cited by 386 · see citing works
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain
Ng, K. P., Pascoal, T. A., Mathotaarachchi, S. S., Therriault, J., Kang, M. S., Shin, M., Guiot, M.-C., Guo, Q., Harada, R., Comley, R. A., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0253-y · Cited by 346 · see citing works
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
Bensimon, G., Ludolph, A., Agid, Y., Vidailhet, M., Payan, C., & Leigh, P. N. (2008) · Brain · doi:10.1093/brain/awn291 · Cited by 345 · see citing works
Progressive Supranuclear Palsy: Pathology and Genetics
Dickson, D. W., Rademakers, R., & Hutton, M. L. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00054.x · Cited by 314 · see citing works
18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy
Passamonti, L., Rodríguez, P. V., Hong, Y. T., Allinson, K. S. J., Williamson, D., Borchert, R. J., Sami, S. A. K., Cope, T., Bevan-Jones, W. R., Jones, P. S., et al. (2016) · Brain · doi:10.1093/brain/aww340 · Cited by 207 · see citing works
Pathological correlations of [F‐18]‐AV‐1451 imaging in non‐alzheimer tauopathies
Marquié, M., Normandin, M. D., Meltzer, A. C., Siao Tick Chong, M., Andrea, N. V., Antón‐Fernández, A., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24844 · Cited by 190 · see citing works
Self-citationSander, K., Lashley, T., Gami, P., Gendron, T., Lythgoe, M. F., Rohrer, J. D., Schott, J. M., Revesz, T., Fox, N. C., & Årstad, E. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.01.003 · Cited by 187 · see citing works
[<sup>18</sup>F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy
Whitwell, J. L., Lowe, V. J., Tosakulwong, N., Weigand, S. D., Senjem, M. L., Schwarz, C. G., Spychalla, A. J., Petersen, R. C., Jack, C. R., & Josephs, K. A. (2017) · Movement Disorders · doi:10.1002/mds.26834 · Cited by 159 · see citing works
Hashimoto, H., Kawamura, K., Igarashi, N., Takei, M., Fujishiro, T., Aihara, Y., Shiomi, S., Muto, M., Ito, T., Furutsuka, K., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.139550 · Cited by 151 · see citing works
Differential clinicopathologic and Genetic features of late-onset amnestic dementias
Murray, M., Cannon, A., Graff-Radford, N., Liesinger, A. M., Rutherford, N., Ross, O., Duara, R., Carrasquillo, M., Rademakers, R., & Dickson, D. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1302-2 · Cited by 150 · see citing works
<i>In vivo</i>imaging of neuromelanin in Parkinson’s disease using<sup>18</sup>F-AV-1451 PET
Hansen, A. K., Knudsen, K., Lillethorup, T. P., Landau, A. M., Parbo, P., Fedorova, T., Audrain, H., Bender, D., Østergaard, K., Brooks, D. J., et al. (2016) · Brain · doi:10.1093/brain/aww098 · Cited by 128 · see citing works
Josephs, K. A., Whitwell, J. L., Tacik, P., Duffy, J. R., Senjem, M. L., Tosakulwong, N., Jack, C. R., Lowe, V., Dickson, D. W., & Murray, M. E. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1618-1 · Cited by 127 · see citing works
Subcortical <sup>18</sup>F‐AV‐1451 binding patterns in progressive supranuclear palsy
Cho, H., Choi, J. Y., Hwang, M. S., Lee, S. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2017) · Movement Disorders · doi:10.1002/mds.26844 · Cited by 119 · see citing works
Smith, R., Schain, M., Nilsson, C., Strandberg, O., Olsson, T., Hägerström, D., Jögi, J., Borroni, E., Schöll, M., Honer, M., et al. (2017) · Movement Disorders · doi:10.1002/mds.26813 · Cited by 118 · see citing works
Reference Tissue–Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging
Baker, S. L., Lockhart, S. N., Price, J. C., He, M., Huesman, R. H., Schonhaut, D. R., Faria, J., Rabinovici, G. D., & Jagust, W. J. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.175273 · Cited by 113 · see citing works
Self-citationPET Quantification of Tau Pathology in Human Brain with 11C-PBB3
Kimura, Y., Ichise, M., Ito, H., Shimada, H., Ikoma, Y., Seki, C., Takano, H., Kitamura, S., Shinotoh, H., Kawamura, K., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.160127 · Cited by 110 · see citing works
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110 · see citing works
Tau imaging with [<sup>18</sup>F]<scp>THK</scp>‐5351 in progressive supranuclear palsy
Ishiki, A., Harada, R., Okamura, N., Tomita, N., Rowe, C. C., Villemagne, V. L., Yanai, K., Kudo, Y., Arai, H., Furumoto, S., et al. (2017) · European Journal of Neurology · doi:10.1111/ene.13164 · Cited by 92 · see citing works
McMillan, C. T., Irwin, D. J., Nasrallah, I., Phillips, J. S., Spindler, M., Rascovsky, K., Ternes, K., Jester, C., Wolk, D. A., Kwong, L. K., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1640-3 · Cited by 87 · see citing works
Self-citationBoxer, A. L., Gold, M., Huey, E. D., Gao, F., Burton, E. A., Chow, T. W., Kao, A. W., Leavitt, B. R., Lamb, B. T., Grether, M. E., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.03.002 · Cited by 82 · see citing works
Self-citationAdvances in the development of tau PET radiotracers and their clinical applications
Okamura, N., Harada, R., Furukawa, K., Furumoto, S., Tago, T., Yanai, K., Arai, H., & Kudo, Y. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2015.12.010 · Cited by 67 · see citing works
Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy.
Smith, R., Schöll, M., Honer, M., Nilsson, C. F., Englund, E., & Hansson, O. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1650-1 · Cited by 62 · see citing works
Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology
Hahn, A., Schain, M., Erlandsson, M., Sjölin, P., James, G. M., Strandberg, O. T., Hägerström, D., Lanzenberger, R. R., Jögi, J., Olsson, T. G., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.174508 · Cited by 57 · see citing works
Positron emission tomography imaging of tau pathology in progressive supranuclear palsy
Coakeley, S., Cho, S. S., Koshimori, Y., Rusjan, P., Harris, M., Ghadery, C., Kim, J., Lang, A. E., Wilson, A. A., Houle, S., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16683695 · Cited by 55 · see citing works
Lurito (2000) · doi:10.1002/1097-0193(200007)10:3
Flagged first, then by citations
Cited by
Sorted by citations
Imaging the evolution and pathophysiology of Alzheimer disease
Jagust, W. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0067-3 · Cited by 604 · see citing works
Self-citationDistribution patterns of tau pathology in progressive supranuclear palsy
Kovacs, G. G., Lukic, M. J., Irwin, D. J., Arzberger, T., Respondek, G., Lee, E. B., Coughlin, D., Giese, A., Grossman, M., Kurz, C., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02158-2 · Cited by 483 · see citing works
Self-citationOssenkoppele, R., Rabinovici, G. D., Smith, R., Cho, H., Schöll, M., Strandberg, O., Palmqvist, S., Mattsson, N., Janelidze, S., Santillo, A., et al. (2018) · JAMA · doi:10.1001/jama.2018.12917 · Cited by 472 · see citing works
Self-citationFleisher, A. S., Pontecorvo, M. J., Devous, M. D., Lu, M., Arora, A. K., Truocchio, S. P., Aldea, P., Flitter, M., Locascio, T., Devine, M., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0528 · Cited by 448 · see citing works
Self-citationTargeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models
Silva, M. C., Ferguson, F. M., Cai, Q., Donovan, K. A., Nandi, G., Patnaik, D., Zhang, T., Huang, H.-T., Lucente, D. E., Dickerson, B. C., et al. (2019) · eLife · doi:10.7554/elife.45457 · Cited by 283 · see citing works
Self-citationPontecorvo, M. J., Devous, M. D., Kennedy, I., Navitsky, M., Lu, M., Galante, N., Salloway, S., Doraiswamy, P. M., Southekal, S., Arora, A. K., et al. (2019) · Brain · doi:10.1093/brain/awz090 · Cited by 249 · see citing works
Self-citation18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
Tsai, R. M., Bejanin, A., Lesman-Segev, O., LaJoie, R., Visani, A., Bourakova, V., O’Neil, J. P., Janabi, M., Baker, S., Lee, S. E., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0470-7 · Cited by 164 · see citing works
Self-citationNeuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy
Malpetti, M., Passamonti, L., Rittman, T., Jones, P. S., Vázquez Rodríguez, P., Bevan‐Jones, W. R., Hong, Y. T., Fryer, T. D., Aigbirhio, F. I., O'Brien, J. T., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25911 · Cited by 83 · see citing works
Neuroinflammation predicts disease progression in progressive supranuclear palsy
Malpetti, M., Passamonti, L., Jones, P. S., Street, D., Rittman, T., Fryer, T. D., Hong, Y. T., Vàsquez Rodriguez, P., Bevan-Jones, W. R., Aigbirhio, F. I., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-325549 · Cited by 85 · see citing works
Ikeda, A., Shimada, H., Nishioka, K., Takanashi, M., Hayashida, A., Li, Y., Yoshino, H., Funayama, M., Ueno, Y., Hatano, T., et al. (2019) · Movement Disorders · doi:10.1002/mds.27623 · Cited by 22 · see citing works
Strobel, J., Müller, H.-P., Ludolph, A. C., Beer, A. J., Sollmann, N., & Kassubek, J. (2023) · Cells · doi:10.3390/cells12242776 · Cited by 10 · see citing works
- Authors
- Schonhaut, D. R., McMillan, C. T., Spina, S., Dickerson, B. C., Siderowf, A., Devous, M. D., Tsai, R., Winer, J., Russell, D. S., Litvan, I., Roberson, E. D., Seeley, W. W., Grinberg, L. T., Kramer, J. H., Miller, B. L., Pressman, P., Nasrallah, I., Baker, S. L., Gomperts, S. N., Johnson, K. A., Grossman, M., Jagust, W. J., Boxer, A. L., & Rabinovici, G. D.
- Affiliations
- University of California, San Francisco (US)
- University of Pennsylvania (US)
- Harvard University (US)
- Avid Radiopharmaceuticals (United States) (US)
- University of California, Berkeley (US)
- Institute for Neurodegenerative Disorders (US)
- University of California San Diego (US)
- University of Alabama at Birmingham (US)
- Corresponding author
- Rabinovici, Gil D.
- ORCID
- Schonhaut, Daniel R.
- McMillan, Corey T.
- Spina, Salvatore
- Dickerson, Bradford C.
- Siderowf, Andrew
- Devous, Michael D.
- Tsai, Richard
- Winer, Joseph
- Russell, David S.
- Litvan, Irene
- Roberson, Erik D.
- Seeley, William W.
- Grinberg, Lea T.
- Kramer, Joel H.
- Miller, Bruce L.
- Pressman, Peter
- Nasrallah, Ilya
- Baker, Suzanne L.
- Gomperts, Stephen N.
- Johnson, Keith A.
- Grossman, Murray
- Jagust, William J.
- Boxer, Adam L.
- Rabinovici, Gil D.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2017-10
- Volume
- 82
- Issue
- 4
- Pages
- 622-634
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC5665658
- OpenAlex
- W2783694534
- Cited by
- 175
- References
- 48
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 11 · 2023: 16 · 2022: 23 · 2021: 29 · 2020: 21 · 2019: 30 · 2018: 20 · 2017: 3
- FWCI
- 14.09
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute on Aging (R01‐AG038791, U54‐NS092089, P01‐AG019724, K08‐AG052648)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- 18F-flortaucipir, tau PET, progressive supranuclear palsy, Parkinson's disease, tau aggregation, globus pallidus, corticobasal degeneration, differential diagnosis, amyloid PET, standardized uptake value ratio
- MeSH terms
- Aged, Aniline Compounds, Brain, Brain Mapping, Carbolines, Cognition Disorders, Diagnosis, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neuropsychological Tests, Parkinson Disease, Severity of Illness Index, Supranuclear Palsy, Progressive, Thiazoles, Case-Control Studies, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
